Enorama Pharma AB (publ)

Stockholm Stock Exchange ERMA.ST

Enorama Pharma AB (publ) EBIT Margin for the year ending December 31, 2023: -3,220.18%

Enorama Pharma AB (publ) EBIT Margin is -3,220.18% for the year ending December 31, 2023, a -440.98% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

Enorama Pharma AB (publ) EBIT Margin for the year ending December 31, 2022 was -595.25%, a -143.85% change year over year.
Enorama Pharma AB (publ) EBIT Margin for the year ending December 31, 2021 was -244.11%, a 77.23% change year over year.
Enorama Pharma AB (publ) EBIT Margin for the year ending December 31, 2020 was -1,072.27%, a -256.73% change year over year.
Enorama Pharma AB (publ) EBIT Margin for the year ending December 31, 2019 was -300.58%, a -1.98% change year over year.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

Stockholm Stock Exchange: ERMA.ST

Enorama Pharma AB (publ)

CEO	Mr. Daniel Schroder
IPO Date	June 10, 2016
Location	Sweden
Headquarters	Södergatan 3
Employees	5
Sector	Consumers Staples
Industries Tobacco Biotechnology Dental Care Personal Care Pharmaceuticals Plastics Snack Foods Soft Drinks & Sodas

Description

Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells medicated chewing gum containing proven generic substances in Sweden. It offers nicotine chewing gum for smoking cessation and medical cannabis chewing gums for non-pharma applications, as well as for other applications, such as oromucosal drug delivery and allergic rhinitis. The company is based in Malmö, Sweden.

Key trends

Past 5 years